查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1513334

周邊動脈疾病市場：依產品類型、最終用戶分類：2024-2035 年全球機會分析與產業預測

Peripheral Artery Disease Market By Product Type (Devices, Drugs), By End User (Hospitals, Specialty Clinics): Global Opportunity Analysis and Industry Forecast, 2024-2035
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
2023年，全球周邊動脈疾病市場價值為45億美元，預計2024年至2035年複合年成長率為7.7%，到2035年將達到108億美元。周邊動脈疾病是一種以向四肢（通常是腿部）供血的動脈狹窄或阻塞為特徵的疾病。發生這種情況是因為脂肪沉積物（斑塊）在動脈中積聚，這個過程稱為動脈粥狀硬化。結果，流向腿部的血液受到限制，導致腿部疼痛、抽筋、麻木和無力等症狀，尤其是在運動時。周邊動脈疾病的治療旨在控制症狀、預防併發症和改善血流。可能需要進行手術來打開阻塞的動脈並恢復血流。這些包括血管成形術（用球囊擴張動脈）和置入術（保持動脈開放）。
周邊動脈疾病市場-IMG1
周邊動脈疾病市場的成長歸因於老年人口的增加和微創手術技術的進步。根據世界衛生組織（WHO）2022年報告，老年人口（60歲以上）估計約佔全球人口的22%。隨著年齡的成長，患周邊動脈疾病的風險會增加，尤其是患有糖尿病、高血壓和吸煙史等其他心血管危險因素的人。隨著許多國家的人口結構轉向老年人口，周邊動脈疾病的發生率和盛行率預計將上升。美國國家醫學圖書館 2023 年的報告稱，70 歲以上族群的周邊動脈疾病發生率增至 20%。因此，由於老年人口的周邊動脈疾病盛行率較高，預計老年人口的增加將對周邊動脈疾病周邊動脈疾病的成長產生正面影響。此外，微創手術的技術進步已成為周邊動脈疾病市場的主要驅動力，改變了診斷和治療格局。血管成形術、置入術和動脈粥狀硬化斑塊切除術等微創技術為傳統開放性手術提供了更安全、更有效的替代方案，徹底改變了周邊動脈疾病的治療。與傳統手術方法相比，這些手術切口較小，對周圍組織的創傷更小，恢復時間更快，且併發症的風險更低。例如，領先的醫療設備製造商 Medtronic Plc 提供完整的 SE 血管支架系統。完整的SE血管支架系統旨在治療股淺動脈和膕動脈近端的周邊動脈疾病。此支架的設計目的是在血管成形術後透過支撐動脈來打開阻塞的動脈並恢復血流。周邊動脈疾病市場按產品類型、最終用戶和地區進行細分。依產品類型分類，市場分為藥品和器材。依最終用戶分類，市場分為醫院、專科診所和門診手術中心。按地區分類，北美（美國、加拿大、墨西哥）、歐洲（德國、法國、英國、義大利、西班牙、其他歐洲國家地區）、亞太地區（日本、中國、澳洲、印度、韓國、其他亞洲地區） -太平洋地區），以南美洲地區（巴西、沙烏地阿拉伯、非洲和其他南美地區）為分析對象。周邊動脈疾病市場的主要企業包括飛利浦公司、博朗梅爾松根公司、美敦力公司、拜耳公司、波士頓科學公司、Becton Dickinson and Company、Terumo Medical Corporation、Biotronik、Cardinal Health 和 Abbott。主要企業正在採用產品核可作為關鍵發展策略，以改善其在周邊動脈疾病市場的產品系列對相關人員的主要好處
  • 該報告提供了 2023 年至 2035 年周邊動脈疾病市場分析的細分市場、當前趨勢、估計/趨勢和動態的定量分析，並確定了一般周邊動脈疾病市場機會。
  • 我們提供市場研究以及與市場促進因素、市場限制和市場機會相關的資訊。
  • 波特的五力分析強調買家和供應商幫助相關人員做出利潤驅動的商業決策並加強供應商和買家網路的潛力。
  • 周邊動脈疾病市場細分的詳細分析有助於確定市場機會。
  • 每個地區的主要國家都根據其對全球市場的收益貢獻繪製了地圖。
  • 市場參與者定位有助於基準化分析，並提供對市場參與者當前地位的清晰了解。
  • 該報告包括對區域和全球周邊動脈疾病市場趨勢、主要企業、細分市場、應用領域和市場成長策略的分析。

目錄

第1章簡介

第 2 章執行摘要

第3章市場概況

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章周邊動脈疾病市場：依產品類型

  • 概述
  • 裝置
    • 設備周邊動脈疾病市場：依設備類型
  • 藥品
    • 按藥物類型周邊動脈疾病市場

第5章周邊動脈疾病市場：依最終用戶分類

  • 概述
  • 醫院
  • 專科診所

第6章周邊動脈疾病市場：按地區

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 拉丁美洲/中東/非洲
    • 巴西
    • 沙烏地阿拉伯
    • 南非
    • 其他

第7章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 2023年主要企業定位

第8章 公司簡介

  • Koninklijke Philips NV
  • B. Braun Melsungen AG
  • Medtronic
  • Bayer AG
  • Boston Scientific Corporation
  • Becton Dickinson and Company
  • Terumo Medical Corporation
  • Biotronik SE & Co. KG
  • Cardinal Health
  • Abbott Laboratories
Product Code: A03968
The global peripheral artery disease market was valued at $4.5 billion in 2023, and is estimated to reach $10.8 billion by 2035, growing at a CAGR of 7.7% from 2024 to 2035. Peripheral artery disease is a condition characterized by the narrowing or blockage of arteries that supply blood to the limbs, typically the legs. This occurs due to the buildup of fatty deposits (plaques) in the arteries, a process known as atherosclerosis. As a result, blood flow to the legs is restricted, leading to symptoms such as leg pain, cramping, numbness, and weakness, particularly during physical activity. Treatment for peripheral artery disease aims to manage symptoms, prevent complications, and improve blood flow. Procedures or surgeries may be required to open blocked arteries and restore blood flow. These can include angioplasty (where a balloon is used to widen the artery) or stent placement (to keep the artery open).
Peripheral Artery Disease Market - IMG1
The peripheral artery disease market growth is attributed to rise in geriatric population, and technological advancements in minimally invasive surgical technology. According to 2022 report by World Health Organization, it was estimated that, the geriatric population (aged 60 and above) is expected to contribute about 22% of global population. As people age, the risk of developing peripheral artery disease rises, especially among those with other cardiovascular risk factors such as diabetes, hypertension, and smoking history. With populations in many countries experiencing a demographic shift towards older age brackets, the incidence and prevalence of peripheral artery disease are expected to escalate. According to the 2023 report by the National Library of Medicine, it was reported that incidence of peripheral artery disease increases to as high as 20% in people over the age of 70. Thus, as the geriatric population has a higher incidence rate of peripheral artery disease, the rise in geriatric population is expected to positively impact the growth of peripheral artery disease market.In addition, technological advancements in minimally invasive procedures have emerged as a major driver for the peripheral artery disease market, transforming the landscape of diagnosis and treatment. Minimally invasive techniques, such as angioplasty, stenting, and atherectomy, have revolutionized the management of peripheral artery disease by offering safer and more effective alternatives to traditional open surgeries. These procedures involve smaller incisions, reduced trauma to surrounding tissues, shorter recovery times, and lower risk of complications compared to conventional surgical approaches. For instance, Medtronic Plc, a leading medical devices company, provides a complete SE vascular stent system. The complete SE vascular stent system is designed to treat peripheral arterial disease in the superficial femoral arteries and proximal popliteal arteries. The stent is designed to open clogged arteries and restore blood flow by providing support to the artery after angioplasty. Thus, the advantages of minimally invasive procedures such as shorter hospital stays and reduced physical trauma (caused in traditional open surgery) are expected to drive the growth of the market.The peripheral artery disease market is segmented by product type, end user, and region. By product type the market is bifurcated into drugs and devices. By end user, the market is divided into hospitals, specialized clinics and ambulatory surgeries centers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA). Major key players that operate in the peripheral artery disease market are Philips N.V., Braun Melsungen AG, Medtronic, Bayer AG, Boston Scientific Corporation, Becton Dickinson and Company, Terumo Medical Corporation, Biotronik, Cardinal Health, Abbott. Key players have adopted product approval as a key developmental strategy to improve the product portfolio of the peripheral artery disease marketKey Benefits For Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the peripheral artery disease market analysis from 2023 to 2035 to identify the prevailing peripheral artery disease market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the peripheral artery disease market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global peripheral artery disease market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Devices
    • Devices type
    • Peripheral Angioplasty Balloons
    • Peripheral Stents
    • Peripheral Catheters
    • Inferior Vena Cava Filters
    • Plaque Modification Devices
    • Hemodynamic Flow Alteration Devices
    • Peripheral Accessories
  • Drugs
    • Drug Type
    • Antiplatelet medicines
    • Statins
    • Anti Hypertensive Medication
    • Others

By End User

  • Specialty Clinics
  • Hospitals

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Koninklijke Philips N.V.
    • B. Braun Melsungen AG
    • Medtronic
    • Bayer AG
    • Boston Scientific Corporation
    • Becton Dickinson and Company
    • Terum

Medical Corporation

    • Biotronik SE & Co. KG
    • Cardinal Health
    • Abbott Laboratories

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Devices
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Devices Peripheral Artery Disease Market by Devices type
  • 4.3. Drugs
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
    • 4.3.4. Drugs Peripheral Artery Disease Market by Drug Type

CHAPTER 5: PERIPHERAL ARTERY DISEASE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Specialty Clinics
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PERIPHERAL ARTERY DISEASE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by Product Type
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Market size and forecast, by Product Type
      • 6.2.4.1.2. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Market size and forecast, by Product Type
      • 6.2.4.2.2. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Market size and forecast, by Product Type
      • 6.2.4.3.2. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by Product Type
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Market size and forecast, by Product Type
      • 6.3.4.1.2. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Market size and forecast, by Product Type
      • 6.3.4.2.2. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Market size and forecast, by Product Type
      • 6.3.4.3.2. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Market size and forecast, by Product Type
      • 6.3.4.4.2. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Market size and forecast, by Product Type
      • 6.3.4.5.2. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Market size and forecast, by Product Type
      • 6.3.4.6.2. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by Product Type
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Market size and forecast, by Product Type
      • 6.4.4.1.2. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Market size and forecast, by Product Type
      • 6.4.4.2.2. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Market size and forecast, by Product Type
      • 6.4.4.3.2. Market size and forecast, by End User
      • 6.4.4.4. India
      • 6.4.4.4.1. Market size and forecast, by Product Type
      • 6.4.4.4.2. Market size and forecast, by End User
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Market size and forecast, by Product Type
      • 6.4.4.5.2. Market size and forecast, by End User
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Market size and forecast, by Product Type
      • 6.4.4.6.2. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by Product Type
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Market size and forecast, by Product Type
      • 6.5.4.1.2. Market size and forecast, by End User
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Market size and forecast, by Product Type
      • 6.5.4.2.2. Market size and forecast, by End User
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Market size and forecast, by Product Type
      • 6.5.4.3.2. Market size and forecast, by End User
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Market size and forecast, by Product Type
      • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product mapping of top 10 player
  • 7.4. Competitive dashboard
  • 7.5. Competitive heatmap
  • 7.6. Top player positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Koninklijke Philips N.V.
    • 8.1.1. Company overview
    • 8.1.2. Key executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
    • 8.1.7. Key strategic moves and developments
  • 8.2. B. Braun Melsungen AG
    • 8.2.1. Company overview
    • 8.2.2. Key executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
    • 8.2.7. Key strategic moves and developments
  • 8.3. Medtronic
    • 8.3.1. Company overview
    • 8.3.2. Key executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. Bayer AG
    • 8.4.1. Company overview
    • 8.4.2. Key executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Boston Scientific Corporation
    • 8.5.1. Company overview
    • 8.5.2. Key executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Becton Dickinson and Company
    • 8.6.1. Company overview
    • 8.6.2. Key executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Terumo Medical Corporation
    • 8.7.1. Company overview
    • 8.7.2. Key executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Biotronik SE & Co. KG
    • 8.8.1. Company overview
    • 8.8.2. Key executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
    • 8.8.7. Key strategic moves and developments
  • 8.9. Cardinal Health
    • 8.9.1. Company overview
    • 8.9.2. Key executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
    • 8.9.7. Key strategic moves and developments
  • 8.10. Abbott Laboratories
    • 8.10.1. Company overview
    • 8.10.2. Key executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance
    • 8.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 02. PERIPHERAL ARTERY DISEASE MARKET FOR DEVICES, BY REGION, 2023-2035 ($MILLION)
  • TABLE 03. GLOBAL DEVICES PERIPHERAL ARTERY DISEASE MARKET, BY DEVICES TYPE, 2023-2035 ($MILLION)
  • TABLE 04. PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 05. GLOBAL DRUGS PERIPHERAL ARTERY DISEASE MARKET, BY DRUG TYPE, 2023-2035 ($MILLION)
  • TABLE 06. GLOBAL PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 07. PERIPHERAL ARTERY DISEASE MARKET FOR HOSPITALS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 08. PERIPHERAL ARTERY DISEASE MARKET FOR SPECIALTY CLINICS, BY REGION, 2023-2035 ($MILLION)
  • TABLE 09. PERIPHERAL ARTERY DISEASE MARKET, BY REGION, 2023-2035 ($MILLION)
  • TABLE 10. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 11. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 12. NORTH AMERICA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 13. U.S. PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 14. U.S. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 15. CANADA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 16. CANADA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 17. MEXICO PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 18. MEXICO PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 19. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 20. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 21. EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 22. GERMANY PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 23. GERMANY PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 24. FRANCE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 25. FRANCE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 26. UK PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 27. UK PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 28. ITALY PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 29. ITALY PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 30. SPAIN PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 31. SPAIN PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 32. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 33. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 34. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 35. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 36. ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 37. JAPAN PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 38. JAPAN PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 39. CHINA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 40. CHINA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 41. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 42. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 43. INDIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 44. INDIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 45. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 46. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 47. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 48. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 49. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 50. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 51. LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY COUNTRY, 2023-2035 ($MILLION)
  • TABLE 52. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 53. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 54. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 55. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 56. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 57. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 58. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023-2035 ($MILLION)
  • TABLE 59. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023-2035 ($MILLION)
  • TABLE 60. KONINKLIJKE PHILIPS N.V.: KEY EXECUTIVES
  • TABLE 61. KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • TABLE 62. KONINKLIJKE PHILIPS N.V.: PRODUCT SEGMENTS
  • TABLE 63. KONINKLIJKE PHILIPS N.V.: SERVICE SEGMENTS
  • TABLE 64. KONINKLIJKE PHILIPS N.V.: PRODUCT PORTFOLIO
  • TABLE 65. KONINKLIJKE PHILIPS N.V.: KEY STRATEGIES
  • TABLE 66. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 67. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 68. B. BRAUN MELSUNGEN AG: PRODUCT SEGMENTS
  • TABLE 69. B. BRAUN MELSUNGEN AG: SERVICE SEGMENTS
  • TABLE 70. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 71. B. BRAUN MELSUNGEN AG: KEY STRATEGIES
  • TABLE 72. MEDTRONIC: KEY EXECUTIVES
  • TABLE 73. MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 74. MEDTRONIC: PRODUCT SEGMENTS
  • TABLE 75. MEDTRONIC: SERVICE SEGMENTS
  • TABLE 76. MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 77. MEDTRONIC: KEY STRATEGIES
  • TABLE 78. BAYER AG: KEY EXECUTIVES
  • TABLE 79. BAYER AG: COMPANY SNAPSHOT
  • TABLE 80. BAYER AG: PRODUCT SEGMENTS
  • TABLE 81. BAYER AG: SERVICE SEGMENTS
  • TABLE 82. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 83. BAYER AG: KEY STRATEGIES
  • TABLE 84. BOSTON SCIENTIFIC CORPORATION: KEY EXECUTIVES
  • TABLE 85. BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 86. BOSTON SCIENTIFIC CORPORATION: PRODUCT SEGMENTS
  • TABLE 87. BOSTON SCIENTIFIC CORPORATION: SERVICE SEGMENTS
  • TABLE 88. BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 89. BOSTON SCIENTIFIC CORPORATION: KEY STRATEGIES
  • TABLE 90. BECTON DICKINSON AND COMPANY: KEY EXECUTIVES
  • TABLE 91. BECTON DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • TABLE 92. BECTON DICKINSON AND COMPANY: PRODUCT SEGMENTS
  • TABLE 93. BECTON DICKINSON AND COMPANY: SERVICE SEGMENTS
  • TABLE 94. BECTON DICKINSON AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 95. BECTON DICKINSON AND COMPANY: KEY STRATEGIES
  • TABLE 96. TERUMO MEDICAL CORPORATION: KEY EXECUTIVES
  • TABLE 97. TERUMO MEDICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 98. TERUMO MEDICAL CORPORATION: PRODUCT SEGMENTS
  • TABLE 99. TERUMO MEDICAL CORPORATION: SERVICE SEGMENTS
  • TABLE 100. TERUMO MEDICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 101. TERUMO MEDICAL CORPORATION: KEY STRATEGIES
  • TABLE 102. BIOTRONIK SE & CO. KG: KEY EXECUTIVES
  • TABLE 103. BIOTRONIK SE & CO. KG: COMPANY SNAPSHOT
  • TABLE 104. BIOTRONIK SE & CO. KG: PRODUCT SEGMENTS
  • TABLE 105. BIOTRONIK SE & CO. KG: SERVICE SEGMENTS
  • TABLE 106. BIOTRONIK SE & CO. KG: PRODUCT PORTFOLIO
  • TABLE 107. BIOTRONIK SE & CO. KG: KEY STRATEGIES
  • TABLE 108. CARDINAL HEALTH: KEY EXECUTIVES
  • TABLE 109. CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 110. CARDINAL HEALTH: PRODUCT SEGMENTS
  • TABLE 111. CARDINAL HEALTH: SERVICE SEGMENTS
  • TABLE 112. CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 113. CARDINAL HEALTH: KEY STRATEGIES
  • TABLE 114. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 115. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 116. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 117. ABBOTT LABORATORIES: SERVICE SEGMENTS
  • TABLE 118. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 119. ABBOTT LABORATORIES: KEY STRATEGIES

LIST OF FIGURES

  • FIGURE 01. PERIPHERAL ARTERY DISEASE MARKET, 2023-2035
  • FIGURE 02. SEGMENTATION OF PERIPHERAL ARTERY DISEASE MARKET,2023-2035
  • FIGURE 03. TOP IMPACTING FACTORS IN PERIPHERAL ARTERY DISEASE MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN PERIPHERAL ARTERY DISEASE MARKET (2024-2035)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL PERIPHERAL ARTERY DISEASE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. PERIPHERAL ARTERY DISEASE MARKET, BY PRODUCT TYPE, 2023 AND 2035(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR DEVICES, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR DRUGS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 14. PERIPHERAL ARTERY DISEASE MARKET, BY END USER, 2023 AND 2035(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR HOSPITALS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PERIPHERAL ARTERY DISEASE MARKET FOR SPECIALTY CLINICS, BY COUNTRY 2023 AND 2035(%)
  • FIGURE 17. PERIPHERAL ARTERY DISEASE MARKET BY REGION, 2023 AND 2035(%)
  • FIGURE 18. U.S. PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 19. CANADA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 20. MEXICO PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 21. GERMANY PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 22. FRANCE PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 23. UK PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 24. ITALY PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 25. SPAIN PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 26. REST OF EUROPE PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 27. JAPAN PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 28. CHINA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 29. AUSTRALIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 30. INDIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 31. SOUTH KOREA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 32. REST OF ASIA-PACIFIC PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 33. BRAZIL PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 34. SAUDI ARABIA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 35. SOUTH AFRICA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 36. REST OF LAMEA PERIPHERAL ARTERY DISEASE MARKET, 2023-2035 ($MILLION)
  • FIGURE 37. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 38. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 39. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 40. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 41. COMPETITIVE DASHBOARD
  • FIGURE 42. COMPETITIVE HEATMAP: PERIPHERAL ARTERY DISEASE MARKET
  • FIGURE 43. TOP PLAYER POSITIONING, 2023